Coccidioidomycosis After Solid Organ Transplantation

Lung and Heart–Lung Transplantation

Volumn , Issue , 2006, Pages 527-547

  Kubak, Bernard M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882900881     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420019285-27     Document Type: Chapter

References (72)

1. Ampel NM, Wieden MA, Galgiani JN. Coccidioidomycosis: clinical update. Rev Infect Dis 1989; 11:897–911.
2. Ampel NM. Combating opportunistic infections: coccidioidomycosis. Expert Opin Pharmacother 2004; 5:255–261.
3. Arsura EL, Bellinghausen PL, Kilgore WB, Abraham JJ, Johnson RH. Septic shock in coccidioidomycosis. Crit Care Med 1998; 26:62–65.
4. Blair JE. Coccidioidal pneumonia, arthritis, and soft-tissue infection after kidney transplantation. Transplant Infect Dis 2004; 6:74–76.
5. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33:1536–1544.
6. Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transplant Infect Dis 2003; 5:3–8.
7. Blair JE, Douglas DD. Coccidioidomycosis in liver transplant recipients relocating to an endemic area. Dig Dis Sci 2004; 49:1981–1985.
8. Blair JE, Balan V, Douglas DD, Hentz JG. Incidence and prevalence of coccidioidomycosis in patients with end-stage liver disease. Liver Transplant 2003; 9:843–850.
9. Brewer JH, Parrott CL, Rimland D. Disseminated coccidioidomycosis in a heart transplant recipient. Sabouraudia 1982; 20:261–265.
10. Britt RH, Enzmann DR, Remington JS. Intracranial infection in cardiac transplant recipients. Ann Neurol 1981; 9:107–119.
11. Bronnimann DA, Galgiani JN. Coccidioidomycosis. Eur J Clin Microbiol Infect Dis 1989; 8:466–473.
12. Calhoun DL, Galgiani JN, Sukoski C, Copeland JG. Coccidioidomycosis in recent renal or cardiac transplant recipients. In: Einstein HE, Catanzaro A, eds. Proceedings of the 4th International Conference on Coccidioidomycosis. Washington, DC: National Foundation for Infectious Diseases, 1985: 312–318.
13. Cha JM, Jung S, Bahng HS, et al. Multi-organ failure caused by reactivated coccidioidomycosis without dissemination in a patient with renal transplantation. Respirology 2000; 5:87–90.
14. Crissey JT, Lang H, Parish LC. Diseases caused by thermally dimorphic fungi. In: Manual of Medical Mycology, 1st ed. Cambride, MA: Blackwell Science, 1995:141–149.
15. Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004; 83:149–175.
16. Deresinski SC, Stevens DA. Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital, Medicine (Baltimore) 1975; 54:377–395.
17. Drutz DJ, Catanzaro A. Coccidioidomycosis. Part II. Am Rev Respir Dis 1978; 117:727–771.
18. Drutz DJ, Catanzaro A. Coccidioidomycosis. Part I. Am Rev Respir Dis 1978; 117:559–585.
19. Einstein HE, Johnson RH. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis 1993; 16:349–356.
20. Galgiani JN. Coccidioidomycosis. West J Med 1993; 153–171.
21. Galgiani JN. Coccidioides species. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. New York: John Wiley & Sons 2005:3040–3049.
22. Hall KA, Copeland JG, Zukoski CF, Sethi GK, Galgiani JN. Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection. Transplantation 1993; 55:1422–1424.
23. Hall KA, Sethi GK, Rosado U, Martinez JD, Huston CL, Copeland JG. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant 1993; 12:525–526.
24. Hart PD, Russell E Jr, Remington JS. The compromised host and infection, II. Deep fungal infection. J Infect Dis 1969; 120:169–191.
25. Kauffman CA. Fungal infections in older adults. Clin Infect Dis 2001; 33: 550–555.
26. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis 1996; 2:192–199.
27. Kubak BM,Maree CL, Pegues DA, et al. Infections in kidney transplantation. In: Danovitch GM, ed. Handbook of Kidney Transplantation, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:279–333.
28. Logan JL, Blair JE, Galgiani JN. Coccidioidomycosis complicating solid organ transplantation. Semin Respir Infect 2001; 16:251–256.
29. Pappagianis D. Epidemiology of coccidioidomycosis. In: Stevens DA, ed. Coccidioidomycosis: A Text New York: Plenum Medical Books, 1980:63–85.
30. Stevens DA. Coccidioidomycosis. N Engl J Med 1995; 332:1077–1082.
31. Yoshino MT, Hillman BJ, Galgiani JN. Coccidioidomycosis in renal dialysis and transplant patients: radiologic findings in 30 patients. Am J Roentgenol 1987; 149:989–992.
32. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959–1966.
33. Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 165:113–117.
34. Chaim W, Burstein E. Postpartum infection treatments: a review. Expert Opin Pharmacother 2003; 4:1297–1313.
35. Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489–494.
36. Kaplan JE, Zoschke D, Kisch AL. Withdrawal of immunosuppresive agents in the treatment of disseminated coccidioidomycosis. Am J Med 1980; 68:624–628.
37. Antony S. Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. Clin Infect Dis 2004; 39:879–880.
38. Holt CD, Winston DJ, Kubak B, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997; 24:216–221.
39. Magill SB, Schmahl TM, Sommer J, et al. Coccidioidomycosis-induced thyroiditis and calcitriol-mediated hypercalcemia in a heart transplantation patient. Endocrinologist 1998; 8:299–302.
40. Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol 2004; 42: 2347–2349.
41. Schroter GP, Bakshandeh K, Husberg BS, Well R III. Coccidioidomycosis and renal transplantation. Transplantation 1977; 23:485–489.
42. Serota AI. The efficacy of fluconazole in prevention of coccidioidomycosis following renal transplantation. In: Einstein HE, Catanzaro A, eds. Coccidioidomycosis: Proceedings of the 5th International Conference on Coccidioidomycosis. Bethesda, MD: National Foundation for Infectious Diseases, 1996:248–254.
43. Vartivarian SE, Coudron PE, Markowitz SM. Disseminated coccidioidomycosis. Unusual manifestations in a cardiac transplantation patient. Am J Med 1987; 83:949–952.
44. Yousem SA, Burke CM, Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol 1985; 16:911–923.
45. Zeluff BJ. Fungal pneumonia in transplant recipients. Semin Respir Infect 1990; 5:80–89.
46. Kusne S, Furukawa H, Abu-Elmagd K, et al. Infectious complications after small bowel transplantation in adults: An update. Transplant Proc 1996; 28: 2761–2762.
47. Abuodeh RO, Orbach MJ, Mandel MA, Das A, Galgiani JN. Genetic transformation of Coccidioides immitis facilitated by Agrobacterium tumefaciens. J Infect Dis 2000; 181:2106–2110.
48. Dosanjh A, Theodore J, Pappagianis D. Probable false positive coccidioidal serologic results in patients with cystic fibrosis. Pediatr Transplant 1998; 2:313–317.
49. Eulalio KD, deMacedo RL, Cavalcanti MA, Martins LM, Lazera MS, Wanke B. Coccidioides immitis isolated from armadillos (Dasypus novemcinctus) in the state of Piaui, Northeast Brazil. Mycopathologia 2001; 149:57–61.
50. Fisher MC, Koenig GL, White TJ, et al. Molecular and phenotypic description of Coccidioides posadasii sp nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002; 94:73–84.
51. Fisher MC, Rannala B, Chaturvedi V, Taylor JW. Disease surveillance in recombining pathogens: multilocus genotypes identify sources of human Coccidioides infections. Proc Natl Acad Sci USA 2002; 99:9067–9071.
52. Huppert M, Sun SH, Harrison JL. Morphogenesis throughout saprobic and parasitic cycles of Coccidioides immitis. Mycopathologia 1982; 78:107–122.
53. Bialek R, Kern J, Herrmann T, et al. PCR assays for identification of Coccidioides posadasii based on the nucleotide sequence of the antigen 2/proline-rich antigen. J Clin Microbiol 2004; 42:778–783.
54. Galgiani JN, Ampel NM, Catanzaro A, Johnson RH, Stevens DA, Williams PL. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:658–661.
55. Galgiani JN. Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med 1999; 130:293–300.
56. Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35:1513–1519.
57. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001; 33(Supp 1):S15–S21.
58. Desai SA, Minai OA, Gordon SM, O’Neil B, Wiedemann HP, Arroliga AC. Coccidioidomycosis in non-endemic areas: a case series. Respir Med 2001; 95:305–309.
59. Tripathy U, Yung GL, Kriett JM, Thistlethwaite PA, Kapelanski DP, Jamieson SW. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg 2002; 73:306–308.
60. Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis 2003; 37:1265–1269.
61. IDSociety.org.
62. Yamada H, Kotaki H, Takahashi T. Recommendations for the treatment of fungal pneumonias. Expert Opin Pharmacother 2003; 4:1241–1258.
63. Perfect JR. Treatment of non-Aspergillus moulds in imrnunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40(Suppl 6): S401–S408.
64. Anstead GM, Corcoran G, Lewis J, et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40:1770–1776.
65. Stevens DA, Rendon A, Gaona V, et al. Posaconazole (POS) therapy for chronic refractory coccidioidomycosis [abstract M-663]. In Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC. Washington, DC: American Society for Microbiology, 2004.
66. Graybill JR, Raad I, Negroni R, et al. Posaconazole (POS) long-term safety in patients with invasive fungal infections (IFIs) [abstract M-1025]. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. Washington, DC: American Society for Microbiology, 2004.
67. Gonzalez GM, Najvar LKL, Tijerina R, et al. Therapeutic efficacy of caspofungin (CAS) alone and in combination with deoxycholate amphotericin B (DAMB) or liposomal amphotericin B (LAMB) for coccidioidomycosis in a mouse model [abstract M-475]. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. Washington, DC: American Society for Microbiology, 2004.
68. Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45: 1854–1859.
69. Gonzalez GM, Tijerina R, Najvar LK, et al. Therapeutic efficacy of amphotericin B lipid complex (AMBLC), amphotericin B colloidal dispersion (AMBCD), liposomal amphotericin B (LAMB), and conventional amphotericin B (AMB) in murine coccicioidomycosis [abstract M-194]. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC. Washington, DC: American Society for Microbiology, 2004.
70. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445–1457.
71. Walsh T, Sable C, Depauw B, et al. A randomized double blind multicenter trial of caspofungin vs. liposomal amphotericin for empirical antifungal therapy of persistently febrile neutropenic patients [abstract M-1761]. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL. Washington, DC: American Society for Microbiology. 2003:477.
72. Crum NF, Groff HL, Parrish JS, Ring W. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis. Clin Infect Dis 2004; 39:e122–e123.